[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Vukasinović Z, Stevanović V, Spasovski D, Zivković Z: [Ewing sarcoma--current opinion]. Srp Arh Celok Lek; 2006 Jul-Aug;134(7-8):348-55
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing tumor family consists of Ewing tumor of bone, extraosseous Ewing tumor, primitive neurectodermal tumor and Askin tumor.
  • All of them share genetic abnormality, reciprocal translocation (11;.
  • 22) (q24; q12), and originate from the same primordial stem cell.
  • Ewing tumor is the most common form, found in 60% of cases.
  • It is the second primary malignant bone tumor.
  • Ewing tumor can develop in virtually any bone of the body and in extraosseous localizations as well, while localization in the extremities occurs in 50% of patients.
  • Paraspinal, retroperitoneal or deep pelvic tumor localization is manifested by back pain.
  • Multimodal chemotherapy with local radiation and/or surgical resection is the best way of modern treatment.
  • Distal parts of extremities and axial skeleton are good prognostic features, while proximal parts, pelvic girdle, metastatic disease and low index of postchemotherapeutic necrosis are associated with poor outcome.
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009618.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 26
  •  go-up   go-down


2. Kara Gedik G, Sari O, Altinok T, Tavli L, Kaya B, Ozcan Kara P: Askin's Tumor in an Adult: Case Report and Findings on 18F-FDG PET/CT. Case Rep Med; 2009;2009:517329

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Askin's Tumor in an Adult: Case Report and Findings on 18F-FDG PET/CT.
  • Primitive neuroectodermal tumor (PNET) of the chest wall or Askin's tumor is a rare neoplasm of chest wall.
  • It most often affects children and adolescents and is a very rare tumor in adults.
  • In this case report, we present an Askin's tumor occurred in a 73-year-old male.
  • The patient was admitted with a history of 3-month lower back pain and cough.
  • In computed tomography, there was a lesion with dimensions of 70 x 40 x 65 mm in the superior segment of the lower lobe of the left lung.
  • Positron emission tomography/computed tomography with 18F-flourodeoxyglucose revealed a pleural-based tumor in the left lung with a maximum standardized uptake value of 4.36.
  • Pathology report with immunocytochemistry was consistent with PNET and the patient received chemotherapy after that.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1293-304 [15788613.001]
  • [Cites] Pediatr Radiol. 1998 Sep;28(9):697-702 [9732497.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):960-2 [8127136.001]
  • [Cites] Clin Radiol. 1991 Jan;43(1):19-23 [1847850.001]
  • [Cites] J Radiol. 1990 Mar;71(3):233-6 [2161926.001]
  • [Cites] Chest. 1990 May;97(5):1252-4 [2331925.001]
  • [Cites] Cancer. 1979 Jun;43(6):2438-51 [222426.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Oct 1;28(19):E408-12 [14520055.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):901-5 [17252575.001]
  • [Cites] Thorax. 2007 Aug;62(8):696-701 [17687098.001]
  • [Cites] Nucl Med Commun. 2006 Jan;27(1):17-24 [16340719.001]
  • (PMID = 20049330.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2797374
  •  go-up   go-down


3. Scurr M, Judson I: How to treat the Ewing's family of sarcomas in adult patients. Oncologist; 2006 Jan;11(1):65-72
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing's sarcoma, peripheral primitive neuroectodermal tumor, and Askin's tumor comprise a single family of tumors, the Ewing's family of tumors, which is characterized by chromosomal translocation.
  • Ewing's sarcoma is known as a malignancy of childhood, but with a median age of 15 years at diagnosis, it should equally be regarded as a malignancy of adolescence and young adulthood.
  • This article examines whether age does affect outcome and treatment in this group of tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Sarcoma, Ewing / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401715.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


Advertisement
4. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA: Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol; 2009 Apr;10(1-2):126-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma: standard and experimental treatment options.
  • OPINION STATEMENT: Ewing sarcoma family tumors (EWS), which include classic Ewing's sarcoma in addition to primitive neuroectodermal tumor and Askin tumor, are the second most common variety of primary bone cancer to afflict adolescents and young adults.
  • Multi-disciplinary care incorporating advances in diagnosis, surgery, chemotherapy, and radiation has substantially improved the survival rate of patients with localized Ewing sarcoma to nearly 70%.
  • This apparent therapeutic plateau exists despite extensive effort during the last four decades to optimize the efficacy of cytotoxic chemotherapy through combination of chemotherapies of mechanistically diverse action, dose-dense scheduling (provided as frequently as every 2 weeks), increased adjuvant treatment duration, and higher dosage per cycle (facilitated with parallel strides in supportive care incorporating growth factors).
  • As has already occurred for malignancies such as breast or colon cancer, the "-omics-based" revolution has enhanced our understanding of the molecular changes responsible for Ewing's tumor formation and identified a number of potential targets (such as IGF-1R or mTOR) amenable to biological therapy.
  • It has also created both a challenge and an opportunity to develop predictive biomarkers capable of selecting patients most likely to benefit from targeted therapy.
  • In this review, we discuss current standard-of-care for patients with Ewing's sarcoma and highlight the most promising experimental therapies in early-phase clinical trials.
  • [MeSH-major] Bone Neoplasms / surgery. Sarcoma, Ewing / surgery. Therapies, Investigational
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Delivery Systems. Drug Screening Assays, Antitumor. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Multicenter Studies as Topic. Oncogene Proteins, Fusion / antagonists & inhibitors. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1. RNA-Binding Protein EWS. Receptor, IGF Type 1 / antagonists & inhibitors. Survival Rate. Transcription Factors / antagonists & inhibitors. Translocation, Genetic. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1975 Jul;36(1):240-51 [1203852.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):132-9 [16317751.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):9-16 [9049825.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):780-6 [17219445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):501-9 [17855013.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):871-7 [18455323.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1451-62 [11142486.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4867-73 [17699866.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Pediatr Blood Cancer. 2004 Sep;43(3):243-9 [15266408.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):516-21 [6772293.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1245-51 [8648380.001]
  • [Cites] Surg Gynecol Obstet. 1967 Feb;124(2):319-24 [5334502.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):795-800 [16411206.001]
  • [Cites] Cancer Chemother Rep. 1972 Oct;56(5):635-9 [4569057.001]
  • [Cites] Blood. 2007 Jan 1;109(1):46-51 [16985182.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1053-8 [14983502.001]
  • [Cites] CA Cancer J Clin. 1972 Mar-Apr;22(2):95-8 [4622125.001]
  • [Cites] Pediatr Blood Cancer. 2008 Sep;51(3):334-8 [18506764.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2812-20 [11387352.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):699-709 [18294840.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):125-35 [9747829.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2611-21 [9215832.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] PLoS Med. 2007 Apr;4(4):e122 [17425403.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):617-24 [18402528.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1322-30 [17317844.001]
  • [Cites] Oncology. 1980;37(2):114-9 [7360479.001]
  • [Cites] Cancer. 1962 Jan-Feb;15:42-9 [14486761.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):471-6 [15049023.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):275-81 [9602261.001]
  • [Cites] Radiology. 2003 Jul;228(1):271-8 [12832588.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1199-207 [16879024.001]
  • [Cites] Cancer. 1969 Jan;23(1):161-6 [5763249.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1428-32 [10197607.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):449-55 [17442235.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1553-9 [9193352.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3622-7 [12429654.001]
  • [Cites] Paediatr Drugs. 2008;10(2):93-105 [18345719.001]
  • [Cites] Onkologie. 2008 Dec;31(12):657-63 [19060503.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):97-105 [18088234.001]
  • [Cites] J Pathol. 2009 Mar;217(4):469-82 [19148905.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Semin Diagn Pathol. 2008 Nov;25(4):304-16 [19013896.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):713-22 [19136249.001]
  • [Cites] Cancer Cell Int. 2008 Nov 17;8:16 [19014694.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):581-4 [19142994.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):358-66 [14648701.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3736-43 [9850016.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7275-83 [15282325.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Nov;17 (11):1703-15 [18922107.001]
  • [Cites] Am J Clin Oncol. 1988 Dec;11(6):614-7 [3189226.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):575-80 [18561167.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):30822-7 [9388225.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11456-60 [1454834.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii97-8 [18456785.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):73-83 [14687792.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):697-705 [7670398.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):23-32 [3334950.001]
  • [Cites] Pediatr Blood Cancer. 2009 Mar;52(3):324-7 [18989890.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41(12):1067-8 [18332914.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4570-4 [8840962.001]
  • [Cites] Am J Surg Pathol. 1984 Dec;8(12):885-98 [6083729.001]
  • [Cites] Cancer Chemother Rep. 1970 Apr;54(2):103-7 [4945999.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):208-13 [2915236.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8 [15838394.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30 [18525458.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5271-6 [17114661.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10 (4):1344-53 [14977835.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):401-6 [11118299.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):429-37 [9052984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77 [12504050.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1248-55 [9552022.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):840-8 [14871959.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Pediatr. 1968 Aug;73(2):249-51 [5668376.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3072-8 [12915596.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Cancer Chemother Rep. 1962 Oct;23:55-60 [13979408.001]
  • [Cites] Cancer. 1974 Feb;33(2):384-93 [4812758.001]
  • [Cites] Oncogene. 2008 May 22;27(23 ):3282-91 [18084326.001]
  • [Cites] Curr Opin Oncol. 2008 Jul;20(4):412-8 [18525337.001]
  • [Cites] Cancer. 1972 Dec;30(6):1522-7 [4641761.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jan;30(1):4-7 [18176172.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3423-30 [12972518.001]
  • [Cites] Cancer. 1979 Jun;43(6):2438-51 [222426.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):814-23 [15897246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):830-8 [15465200.001]
  • (PMID = 19533369.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Number-of-references] 94
  •  go-up   go-down


5. Fresco R, Saldombide L, Suárez L: Synchronous presentation of an Askin tumor and a plasmacytoma in an adult patient. Tumori; 2003 May-Jun;89(3):324-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous presentation of an Askin tumor and a plasmacytoma in an adult patient.
  • Askin tumor, or malignant small round cell tumor of the thoracopulmonary region, is an extremely infrequent entity occurring primarily in children and adolescents.
  • Its histopathologic and cytogenetic features suggest that it belongs to the family of Ewing's sarcoma and primitive neuroectodermal tumors.
  • We report the case of a 43-year-old woman affected by an Askin tumor with bone metastases at diagnosis, presenting synchronously with a plasmacytoma.
  • This is the first reported case of the simultaneous occurrence of an Askin tumor and a malignant hemopathy.
  • The progression of the former and the remission of the plasmacytoma during chemotherapy were remarkable, since Askin tumor treatment shares drugs used for the treatment of plasma cell tumors.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Small Cell / secondary. Neoplasms, Second Primary / pathology. Plasmacytoma / pathology. Thoracic Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908792.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Seddon BM, Whelan JS: Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs; 2008;10(2):93-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.
  • The Ewing sarcoma family of tumors (ESFT) is one of the most common groups of malignancies arising in children, adolescents, and young adults up to approximately 25 years of age.
  • It comprises Ewing sarcoma arising from bone and extraosseous Ewing sarcoma arising from soft tissues (which includes peripheral neuroectodermal tumors and Askin tumor arising from the chest wall).
  • Ewing sarcoma is treated successfully in many cases by a combination of chemotherapy, surgery, and radiotherapy.
  • A number of prognostic factors have been identified that can be used to stratify patients according to the risk of relapse, allowing optimization of treatment.
  • These can be categorized as tumor-related factors (presence of metastases, tumor site, volume, lactic dehydrogenase level, chromosomal translocation type, presence of fusion transcripts in blood and bone marrow), treatment-related factors (local therapy, histologic response to chemotherapy, radiologic response to chemotherapy, chemotherapy regimen), and patient-related factors (gender, age).
  • [MeSH-minor] Age Factors. Antineoplastic Protocols. Combined Modality Therapy. Humans. Pediatrics. Prognosis. Protein Kinases / physiology. Receptor, IGF Type 1 / physiology. Signal Transduction. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):132-9 [16317751.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):9-16 [9049825.001]
  • [Cites] Acta Oncol. 1998;37(7-8):671-6 [10050985.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1664-74 [2213103.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3136-48 [15837770.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 1;87(5):385-6 [7853420.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1245-51 [8648380.001]
  • [Cites] Acta Oncol. 2007;46(5):581-91 [17562434.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1099-105 [9426329.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1053-8 [14983502.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):120-5 [15075902.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2539-53 [2337871.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1049-54 [7566963.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1174-83 [9506366.001]
  • [Cites] J Public Health (Oxf). 2007 Jun;29(2):178-82 [17327364.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2873-6 [15254055.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2812-20 [11387352.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1067-70 [1695726.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3227-38 [8242546.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2243-51 [12441260.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4127-31 [9751624.001]
  • [Cites] J Neurol Sci. 1998 May 7;157(2):129-37 [9619634.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1911-8 [8410118.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):843-6 [9404924.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1322-30 [17317844.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1646-54 [11742482.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8349-56 [15548704.001]
  • [Cites] Oncologist. 2006 Jan;11(1):65-72 [16401715.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):56-60 [9495359.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):275-81 [9602261.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):22-9 [16572419.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):85-91 [12506175.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21(8):795-9 [9603403.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1763-9 [8355043.001]
  • [Cites] Int J Cancer. 1995 Apr 21;64(2):135-9 [7542227.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2704-12 [11289151.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1301-5 [16782749.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3044-52 [9738574.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1553-9 [9193352.001]
  • [Cites] J Bone Joint Surg Am. 2000 May;82(5):667-74 [10819277.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Orthop Res. 2006 Jun;24(6):1138-44 [16705696.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):561-78 [14713267.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):276-83 [10472562.001]
  • [Cites] Cell Death Differ. 2001 May;8(5):506-14 [11423911.001]
  • [Cites] Br J Cancer. 1995 Jul;72(1):96-100 [7599072.001]
  • [Cites] Diagn Mol Pathol. 1998 Jun;7(3):152-7 [9836070.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):329-37 [2448428.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1818-29 [11251014.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2181-8 [11956280.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7275-83 [15282325.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1482-8 [8101562.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1073-7 [10572605.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2006;16(3):193-210 [17073551.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):192-204 [17284103.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4354-62 [15781881.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1713-20 [16121404.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1221-30 [6174200.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):14-21 [16400699.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):23-32 [3334950.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):1010-4 [11314037.001]
  • [Cites] Curr Opin Investig Drugs. 2006 Jun;7(6):501-12 [16784020.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1514-24 [2099751.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5415-24 [15289350.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3997-4002 [16921053.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):468-74 [11070479.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4570-4 [8840962.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9394-407 [16361639.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):870-80 [11157041.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43 [17259557.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3868-76 [15867386.001]
  • [Cites] Semin Cancer Biol. 2003 Aug;13(4):275-81 [14563122.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5134-42 [11016640.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):146-51 [8162068.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5664-74 [15184883.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):767-71 [14551512.001]
  • [Cites] Acta Oncol. 2000;39(1):111-6 [10752664.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):225-32 [15213720.001]
  • [Cites] Eur J Cancer. 2000 May;36(7):875-80 [10785592.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] EMBO J. 1993 Dec;12(12):4481-7 [8223458.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):429-37 [9052984.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1579-91 [1403038.001]
  • [Cites] Mol Ther. 2003 Jun;7(6):811-6 [12788655.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1248-55 [9552022.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):91-6 [16326096.001]
  • [Cites] Acta Oncol. 2006;45(4):469-75 [16760184.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):840-8 [14871959.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1061-9 [9376188.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3072-8 [12915596.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):252-9 [11004677.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):152-9 [16382125.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jun;32(2):229-38 [3163261.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3628-33 [9817284.001]
  • [Cites] J Clin Oncol. 1999 Jun;17 (6):1809-14 [10561219.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):583-8 [9053480.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2573-8 [14642919.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1707-11 [9586882.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9282-7 [14681687.001]
  • (PMID = 18345719.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Number-of-references] 126
  •  go-up   go-down


7. Veronesi G, Spaggiari L, De Pas T, Solli PG, De Braud F, Catalano GP, Curigliano G, Leo F, Pastorino U: Preoperative chemotherapy is essential for conservative surgery of Askin tumors. J Thorac Cardiovasc Surg; 2003 Feb;125(2):428-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy is essential for conservative surgery of Askin tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Pneumonectomy. Preoperative Care / methods. Sarcoma, Small Cell / drug therapy. Sarcoma, Small Cell / surgery. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Postoperative Care / methods. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12579122.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Mulsow J, Jeffers M, McDermott R, Geraghty J, Rothwell J: Complete clinical response to neoadjuvant chemotherapy in a 54-year-old male with Askin tumor. Thorac Cardiovasc Surg; 2010 Aug;58(5):306-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete clinical response to neoadjuvant chemotherapy in a 54-year-old male with Askin tumor.
  • Askin tumor is a tumor of the thoracopulmonary region that most commonly affects children and adolescents.
  • These rare tumors are a form of primitive neuroectodermal tumor and typically carry a poor prognosis.
  • Treatment is multimodal and consists of a combination of neoadjuvant chemotherapy, radical resection, and adjuvant chemo- and radiotherapy or all of the above.
  • We report a case of Askin tumor in a 54-year-old male who showed rapid and complete response to neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroectodermal Tumors, Primitive / drug therapy. Thoracic Neoplasms / drug therapy
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20680911.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Iwamoto Y: Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol; 2007 Feb;37(2):79-89
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of Ewing's sarcoma.
  • Ewing's sarcoma is a small round-cell tumor typically arising in the bones, rarely in soft tissues, of children and adolescents.
  • Ewing's sarcoma has retained the most unfavorable prognosis of all primary musculoskeletal tumors.
  • Prior to the use of multi-drug chemotherapy, long-term survival was less than 10%.
  • The development of multi-disciplinary therapy with chemotherapy, irradiation, and surgery has increased current long-term survival rates in most clinical centers to greater than 50%.
  • In addition, the preferred method of tumor resection has changed; limb salvage has nearly replaced amputation of the affected limb.
  • Recent studies have revealed that the pathognomonic translocations involving the EWS gene on chromosome 22 and an ETS-type gene, which is most commonly the Fli1 gene on chromosome 11, are implicated in more than 95% of Ewing's sarcomas, primitive neuroectodermal tumors and Askin's tumors.
  • Therefore, these lesions have become regarded as a single entity, dubbed the Ewing's family of tumors.
  • RT-PCR to detect EWS-ETS gene arrangements is widely used to confirm the diagnosis of Ewing's family of tumors.
  • Experimental results suggest that inhibition of the signaling pathway downstream of the EWS-ETS gene may lead to the development of molecularly targeted therapy in the future.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17272319.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 61
  •  go-up   go-down


10. Thacker MM, Temple HT, Scully SP: Current treatment for Ewing's sarcoma. Expert Rev Anticancer Ther; 2005 Apr;5(2):319-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment for Ewing's sarcoma.
  • Ewing's sarcoma is the second most common primary bone tumor seen in children and adolescents, and was described by James Ewing in 1921 as a diffuse endothelioma of bone.
  • It is one of the differential diagnoses of pediatric small round blue cell tumors.
  • This is not a single condition, but a group of morphologically and clinically closely related disorders with similar molecular biology -- expression of tumor-specific chimeric oncoproteins through balanced chromosomal translocations involving the EWS gene -- often referred to as the Ewing family of tumors.
  • This includes Ewing's sarcoma of bone, extra-osseous Ewing's sarcoma, Askin tumor and peripheral neuroectodermal tumor.
  • Ewing's sarcoma has therefore been considered as a systemic disease necessitating local as well as systemic treatment.
  • An aggressive multidisciplinary approach has resulted in significant improvement in prognosis for patients with these tumors.
  • Despite aggressive treatment, 20-40% of patients with localized disease and almost 80% of patients with metastatic disease at presentation succumb to the illness.
  • Advances in understanding the molecular biology of these tumors will hopefully result in the development of novel treatment approaches.
  • The aim of this article is to review the existing treatment methods and to highlight the more recent approaches to the treatment of this condition.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Sarcoma, Ewing / drug therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877528.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 123
  •  go-up   go-down


11. Soyer T, Karnak I, Ciftci AO, Senocak ME, Tanyel FC, Büyükpamukçu N: The results of surgical treatment of chest wall tumors in childhood. Pediatr Surg Int; 2006 Feb;22(2):135-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of surgical treatment of chest wall tumors in childhood.
  • Chest wall tumors (CWT) are rarely seen in childhood and surgery constitutes a complementary part of the therapy.
  • The diagnosis was malignant tumor in 12 (70%) and benign in 5 (30%).
  • They were Ewing's sarcoma (ES) (n = 4), primitive neuroectodermal tumor (PNET) (n = 3), Askin's tumor (n = 1), rhabdomyosarcoma (RMS) (n = 2), neuroblastoma (n = 2), osteochondroma (n = 1), aneurysmal bone cyst (n = 2) and hamartoma (n = 2).
  • Preoperative chemotherapy was given to most patients with malignant tumor.
  • All patients had only local tumor at the time of resection.
  • All tumor tissues with the affected rib/ribs were resected en bloc with the adjacent tissues.
  • Patients with benign tumor were free of complaints or complications during follow up.
  • All patients with malignant tumor received postoperative chemotherapy.
  • Five patients developed distant metastasis and two died.
  • Since most of the CWT are malignant and not initially suitable for surgical excision, the management includes tissue diagnosis either by tru-cut or open biopsy.
  • Determination of malignant condition should be followed by an intensive chemotherapy.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Pediatr Surg. 1994 Nov;3(4):267-76 [7850367.001]
  • [Cites] Spine (Phila Pa 1976). 1985 Sep;10 (7):618-22 [4071270.001]
  • [Cites] J Pediatr Surg. 1977 Dec;12(6):991-9 [201742.001]
  • [Cites] J Pediatr Surg. 1980 Dec;15(6):906-12 [7463293.001]
  • [Cites] Plast Reconstr Surg. 1996 Oct;98(5):804-10 [8823018.001]
  • [Cites] J Pediatr Surg. 1999 Dec;34(12):1773-8 [10626852.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):40-4 [3382285.001]
  • [Cites] J Pediatr Surg. 1988 Jul;23(7):667-73 [3204468.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1154-61 [10838532.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):588-91; discussion 591-2 [10047664.001]
  • [Cites] J Spinal Disord. 1994 Dec;7(6):522-7 [7873852.001]
  • [Cites] J Pediatr Surg. 1978 Jun;13(3):275-80 [209164.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • (PMID = 16328338.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


12. Schiavetti A, Varrasso G, Maurizi P, Cappelli C, Clerico A, Properzi E, Castello MA: Ten-day schedule oral etoposide therapy in advanced childhood malignancies. J Pediatr Hematol Oncol; 2000 Mar-Apr;22(2):119-24
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
  • Between April 1995 and February 1999, 15 pretreated patients with high-risk tumors received oral VP-16.
  • The schedule of therapy was oral VP-16 50 mg/m2/day for 10 consecutive days and 1-week interval between cycles.
  • Therapy was stopped after 1 year of treatment or at time of progressive disease or possible surgery.
  • All patients had received parenteral VP-16 in their earlier chemotherapy.
  • RESULTS: Twelve patients were evaluable for tumor response.
  • After 2 to 4 months of treatment, one patient had complete remission (CR), two had partial response (PR), two had minor response (MR), two had mixed response (MxR), three had stable disease (SD), and two had progressive disease (PD).
  • In three patients, oral VP-16 was administered for maintenance therapy.
  • After an average follow-up of 27.5 months (range, 7-41 months), five patients are alive without disease (in three, total surgery was performed after VP-16 therapy) and three patients are alive with disease.
  • One patient had Grade 34 thrombocytopenia; in the remaining patients, no acute toxicity was observed during treatment.
  • Stable disease was observed in three patients, one with an Askin tumor, one with medulloblastoma, and one with hepatoblastoma.
  • Given the possible leukemogenic risk, this schedule should be used as a palliative form of therapy or in patients with poor prognosis..
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Etoposide / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Child. Child, Preschool. Disease Progression. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Patient Compliance. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10779024.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


13. Karatas Silistreli O, Ayhan M, Görgü M, Oztan Y, Sisman N: A primitive neuroectodermal tumor on the face: case report. Acta Chir Plast; 2005;47(2):38-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primitive neuroectodermal tumor on the face: case report.
  • In 1918, Stout defined the lesion in which small round cells originating from the ulnar nerve formed a rosette as neuroepithelioma.
  • It was claimed that this tumor originated from neuroectodermis and was different from the classical neuroblastoma.
  • The term primitive neuroectodermal tumor (PNET) involves a group of tumors of the soft tissue originating from neural crest and resulting from the brain, spinal cord and branches of the sympathetic nervous system.
  • Extracranial primitive neuroectodermal tumors originate from neural crest cells outside the sympathetic and central nervous system.
  • PNET also has some distinctive histological, immunohistochemical and ultrastructural features.
  • It is usually encountered in children and young adults; most frequently located in thoracopulmonary region (Askin's tumor).
  • PNET is an aggressive tumor.
  • It is treated with aggressive surgery as well as chemotherapy and radiotherapy.
  • In this report, we presented a case of PNET located on the right cheek with multiple distant metastases.
  • Clinicians should be on alert when treating facial tumors, not to skip PNET, which is a very aggressive one.
  • [MeSH-major] Facial Neoplasms / surgery. Neuroectodermal Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033149.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Christiansen S, Semik M, Dockhorn-Dworniczak B, Rötker J, Thomas M, Schmidt C, Jürgens H, Winkelmann W, Scheld HH: Diagnosis, treatment and outcome of patients with Askin-tumors. Thorac Cardiovasc Surg; 2000 Oct;48(5):311-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, treatment and outcome of patients with Askin-tumors.
  • Askin tumors are highly malignant small-round-cell tumors of the thoracopulmonary region, which occur rarely.
  • All Askin tumors were diagnosed by histological and immunohistochemical examinations as well as molecular genetic proof of characteristic translocations.
  • In all patients, the tumor arose from the chest wall, infiltrating adjacent ribs and parts of the lung.
  • At the time of first diagnosis, five patients did not reveal any metastases.
  • Treatment consisted of a pre- and postoperative (radio-) chemotherapy according to the EVAIA protocol and a radical tumor resection in all patients.
  • Four patients, in whom primary tumor resection was complete, are alive 14, 20, 35 and 84 months after first diagnosis - only one patient had to undergo a second operation for a local relapse 17 months after first diagnosis.
  • The other 4 patients, who suffered from a very extensive primary tumor, expired 13, 17, 18 and 39 months after the diagnosis was made.
  • Our data demonstrate that Askin tumors require an aggressive multimodality treatment consisting of pre- and postoperative chemotherapy, radical surgical resection and postoperative irradiation, which may be performed preoperatively in selected cases, too.
  • [MeSH-major] Lung Neoplasms. Sarcoma, Small Cell. Thoracic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11100769.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 17
  •  go-up   go-down


15. Nakajima Y, Koizumi K, Hirata T, Hirai K, Fukushima M, Yamagishi S, Kawashima T, Kinoshita H, Shimizu K: Long-term survival of Askin tumor for 10 years with 2 relapses. Ann Thorac Cardiovasc Surg; 2006 Apr;12(2):137-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of Askin tumor for 10 years with 2 relapses.
  • Thoracic CT detected a tumor in contact with the left thoracic wall, and tumorectomy was performed in May 1995.
  • The tumor was diagnosed as a primitive neuroectodermal tumor (PNET).
  • After surgery, the thoracic wall to which the tumor adhered was treated with irradiation at 50 Gy.
  • Chemotherapy was considered, but the patient did not wish to undergo this treatment.
  • [MeSH-major] Lung Neoplasms / secondary. Neuroectodermal Tumors, Primitive / pathology. Sarcoma, Ewing / pathology. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702938.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Lahl M, Fisher VL, Laschinger K: Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship. Clin J Oncol Nurs; 2008 Feb;12(1):89-97
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma family of tumors: an overview from diagnosis to survivorship.
  • The Ewing's sarcoma family of tumors (ESFT) is a malignant primary bone tumor often involving soft tissue that affects not only children but also young adults.
  • Since 1992, with the addition of ifosfamide and etoposide to standard chemotherapy for primary tumors, much improvement has been made in the treatment of ESFT, with a primary focus on children.
  • ESFT, which includes Ewing's sarcoma, extraosseous Ewing's sarcoma, Askin tumor, and primitive neuroectodermal tumor, is the second most common primary malignant bone tumor in children and adolescents.
  • It accounts for 10% of primary malignant bone tumors in children and 3% of all childhood malignancies.
  • Treatment for ESFT consists of a multimodal approach, including chemotherapy, radiation therapy, and surgery.
  • Children and young adults with Ewing's sarcoma face many physical challenges from their illness and the complications of their treatments.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy / adverse effects. Combined Modality Therapy / nursing. Humans. Incidence. Nurse's Role. Oncology Nursing / organization & administration. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258578.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


17. Veldwijk MR, Berlinghoff S, Laufs S, Hengge UR, Zeller WJ, Wenz F, Fruehauf S: Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. Cancer Gene Ther; 2004 Aug;11(8):577-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors.
  • Soft-tissue sarcomas are mesenchymal tumors that respond poorly to systemic chemotherapy.
  • Suicide gene therapy may be an alternative treatment strategy.
  • Here we show a high susceptibility of human sarcoma cell lines for recombinant adeno-associated virus 2 (rAAV-2) suicide vectors: connective tissue sarcoma (HS-1), fibrosarcoma (HT-1080), Ewing sarcoma (RD-ES), Askin tumor (SK-N-MC), rhabdomyosarcoma (A-204) and soft-tissue sarcoma (WSKL-1).
  • A complete eradication of rAAV-2-EF1alpha-TK/eGFP (TK/enhanced green fluorescent protein fusion gene)-transduced tumor cells was shown following exposure to ganciclovir (2.5 microg/ml) in vitro, while at this dose level > 90% of mock-transduced tumor cells survived.
  • Xenotransplantation tumor models (intraperitoneal, subcutaneous) for the human sarcoma cell line HS-1 were established in nonobese diabetic/severe-combined immunodeficient mice.
  • Mice transplanted with rAAV-2-EF1alpha-TK/eGFP-transduced and ganciclovir-exposed tumor cells survived > 5 months while in the nontransduced group all mice had died approximately 1 month after inoculation.
  • These data hold promise for further development of rAAV-2-based suicide gene therapy of sarcomas.
  • [MeSH-major] Dependovirus / genetics. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Genetic Vectors. Sarcoma / therapy. Thymidine Kinase / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytomegalovirus / genetics. Ganciclovir / therapeutic use. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Peptide Elongation Factor 1 / genetics. Promoter Regions, Genetic / genetics. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15280909.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptide Elongation Factor 1; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


18. Mata F, Losa F, Camacho L, Fernandez Trigo V, Barrios P, Mas J: Peripheral primitive neuroectodermal tumor (PPNET) of pelvic origin: report of a case arising from an unusual location. Tumori; 2001 Mar-Apr;87(2):109-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor (PPNET) of pelvic origin: report of a case arising from an unusual location.
  • A peripheral primitive neuroectodermal tumor arising from the abdominopelvic cavity is reported in a 24-year-old young male without any previous remarkable pathology.
  • The diagnostic workup included a CT-guided biopsy which defined the tumor as a sarcomatous type.
  • Radical surgery was performed including tumor resection, pelvic exenteration (bladder and prostate gland) and urinary and fecal diversion.
  • Adjuvant chemotherapy (VAIA) was delivered once the histology was confirmed.
  • We reviewed the available literature focusing on the varied nomenclature of this tumor (peripheral neuroepithelioma, Askin's tumor, Ewing's extraosseous tumor, peripheral adult neuroblastoma, peripheral primitive extracranial neuroectodermal tumor (PPNET), the clinical features, the role of diagnostic imaging techniques, pathologic assessment and controversial therapeutic management.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Infant. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11401207.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mordant P, Le Pimpec-Barthes F, Riquet M: [Neurogenic tumors of the mediastinum in adults]. Rev Pneumol Clin; 2010 Feb;66(1):81-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurogenic tumors of the mediastinum in adults].
  • [Transliterated title] Tumeurs nerveuses du médiastin de l'adulte.
  • In adults, mediastinal neurogenic tumours constitute the third group of mediastinal tumours, after thymomas and lymphomas.
  • If the group of neurogenic tumour is frequent, each type of tumour is relatively unusual in everyday's clinic.
  • Among them, nerve sheath tumours are the more frequent, followed by tumour of the autonomic system.
  • Askin tumour remains uncommon.
  • Treatment of this tumour requires complete preoperative work-up, including standard radiography, CT-scan, MRI, and sometimes nuclear imaging.
  • In most cases, the treatment is based on surgical resection, and may be associated with radiotherapy or chemotherapy in case of malignant tumour or incomplete resection.
  • Better understanding of these tumours, including their molecular abnormalities, may lead to new changes in their classifications, and to their management.
  • [MeSH-major] Ganglia, Autonomic. Ganglioneuroblastoma / surgery. Ganglioneuroma / surgery. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Paraganglioma / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Child. Humans. Prognosis. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20207300.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 64
  •  go-up   go-down


20. Peng RJ, Sun XF, Xiang XJ, Zhen ZJ, Ling JY, Tong GL, Xia Y, Xu GC, Jiang WQ: [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy]. Ai Zheng; 2009 Dec;28(12):1304-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].
  • BACKGROUND AND OBJECTIVE: Ewing's sarcoma family of tumor (ESFT) is aggressive.
  • The optimal therapy modality for ESFT is still to be found.
  • This study was to explore the clinical characteristics and therapy for ESFT.
  • RESULT: Of 92 cases, 23 were Ewing's sarcoma of bone, 21 extraosseous Ewing's sarcoma, 43 peripheral primitive neuroectodermal tumor, and 5 Askin tumor.
  • Median follow-up time was 31.5 months (range, 10-137 months).
  • Thirty-eight patients received multidisciplinary therapy and 19 single model therapy in non-metastasis group.
  • Three-year overall survival (OS) and event-free survival (EFS) were significantly different between non-metastatic multidisciplinary therapy group and non-metastatic single model group (63% vs. 20%, 46% vs. 18%, respectively, P<0.001).
  • The patients who received surgery plus chemotherapy and plus radiation or not had longer survival than those treated with chemotherapy plus radiation in non-metastatic multidisciplinary therapy group (Chi2=7.591, 9.212; P=0.006, 0.002).
  • Cox regression analysis suggested therapy model and response to treatment were independent prognostic factors for ESFT.
  • CONCLUSIONS: Our studying showed multidisciplinary therapy could significantly improve non-metastatic ESFT patients' survival.
  • Chemotherapy plus surgery and plus radiation or not were superior to chemotherapy plus radiation in local control for the non-metastatic ESFT.
  • Therapy model and response were independent prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Infant. Lymphatic Metastasis. Male. Middle Aged. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958626.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CAV protocol
  •  go-up   go-down


21. Yeste L, Sierra A, Cañon R, Aristu J, Torre W: Successful use of intraoperative radiotherapy for local control of an Askin's tumor recurrence. J Cardiovasc Surg (Torino); 2001 Feb;42(1):143-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful use of intraoperative radiotherapy for local control of an Askin's tumor recurrence.
  • Askin s tumor is an infrequent disease, with a high tendency to local recurrence.
  • We present the case of a 16-year-old female diagnosed with a new recurrence of this tumor affecting the thoracic wall.
  • There had been a previous 5-year history of 3 local recurrences treated each time by apparently complete surgery.
  • A multidisciplinary approach consisting of chemotherapy, complete chest tumor resection and intraoperative radiotherapy was undertaken.
  • The role of surgery is still the key to obtaining good survival, but in this case intraoperative radiotherapy proved to be a good adjuvant treatment.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Sarcoma, Small Cell / radiotherapy. Sarcoma, Small Cell / surgery. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Humans. Intraoperative Period

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11292924.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Papi A, Ferreri AM, Rocchi P, Guerra F, Orlandi M: Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Res; 2010 Feb;30(2):535-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
  • Valproic acid (VPA) is an established drug in the long-term therapy of epilepsy.
  • In this study, the anticancer properties of VPA on neural crest-derived human tumor cell lines G361 melanoma, U87MG glioblastoma and SKNMC Askin tumor cells were investigated.
  • The effect of VPA on cell growth, apoptotic activity and invasive ability were evaluated.
  • Firstly, VPA induced cell growth inhibition and apoptotic activity, as demonstrated by sulforhodamine B protein assay, annexin V assay and by Western blot analysis for Bcl2 and Bax expression levels, in all three cell lines.
  • Treatment with VPA caused a decrease in the invasive ability of all three cell lines.
  • Since the invasion process involves a complex system of tightly regulated proteases, matrix metalloproteinases (MMPs) and their tissue-specific inhibitors (TIMPs), the effect of VPA on MMP and TIMP expressions was analysed.
  • Taken together, our results, besides providing further evidence that VPA may represent a promising therapeutic strategy in cancer treatment, may help in the design of new protocols geared at the treatment of neural crest-derived tumors.
  • [MeSH-major] Anticonvulsants / pharmacology. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Melanoma / drug therapy. Thoracic Neoplasms / drug therapy. Valproic Acid / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Matrix Metalloproteinases / metabolism. Neoplasm Invasiveness. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • Genetic Alliance. consumer health - Neural crest tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332466.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Tissue Inhibitor of Metalloproteinase-1; 614OI1Z5WI / Valproic Acid; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


23. Huang DS, Tang SQ, Wang JW, Liu L, Lu S: [Two cases of Askin tumor misdiagnosed as pulmonary tuberculosis]. Zhonghua Er Ke Za Zhi; 2004 Apr;42(4):286
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of Askin tumor misdiagnosed as pulmonary tuberculosis].
  • [MeSH-major] Diagnostic Errors. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Thoracic Neoplasms / diagnosis. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / drug therapy. Child. Diagnosis, Differential. Humans. Male. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15157391.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement